Loading this company
BioMarin Pharmaceutical Inc.
BMRNPrices in USD
TickerWorth ScoreC49/100
What we think
Priced within our range of $46.63 to $108.35.
Price
$55.95USD up +$1.28 (+2.34%)
Quoted · Prices are delayed.
Why did it move today?
Nothing we can cite explains today’s move for this company.
Is it cheap?
Our range from 3 models, on today’s numbers
$46.63–$108.35
What the price needs: revenue growth of 18.1%/yr for 5 years (our model assumes 11.8%).
Led by discounted cash flow (DCF) · Steady cash-flow business
Delayed price used by the model $54.67Prices are delayed.
Is it a good business?
- Valuation67 out of 100
- Growth67 out of 100
- Financial health67 out of 100
- Past performance50 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$91.63 across 27 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It operates in the Biotechnology industry (Healthcare sector), headquartered in United States. The company employs roughly 3,221 people.
Key stats
52-week range$49.26–$70.98
- Open
- $54.84
- Day high
- $55.12
- Day low
- $54.08
- Previous close
- $54.68
- Volume
- 2,995,683 · 1.39× avg
- Average volume
- 2,156,930
- Market cap
- $10,582,677,504.00
- P/E (TTM)
- 147.76
- Earnings per share
- $0.37
- Beta
- 0.22
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Reported quarterly or annual results
- Signed a material agreement
- Disclosed another material event
- Changed leadership or its board
- Disclosed another material event
- Signed a material agreement
- Signed a material agreement
Top news
- Cantor Fitzgerald Reiterates Overweight on BioMarin Pharmaceutical, Maintains $86 Price Target (opens in a new tab)Benzinga
- BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy? (opens in a new tab)Yahoo
- 1cBio Received Shareholder Proceeds Upon Closing of BioMarin Pharmaceutical Inc.'s Acquisition of Alesta Therapeutics (opens in a new tab)Yahoo
- Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $114
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Friberg Gregory RShares withheld (tax) · $245,160.00
- Plenge Robert MGrant / award ·
Not investment advice. TickerWorth Score is a model output.